| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | CDC19 |
| Uniprot No | P00549 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-500aa |
| 氨基酸序列 | SRLERLTSLNVVAGSDLRRTSIIGTIGPKTNNPETLVALRKAGLNIVRMNFSHGSYEYHKSVIDNARKSEELYPGRPLAIALDTKGPEIRTGTTTNDVDYPIPPNHEMIFTTDDKYAKACDDKIMYVDYKNITKVISAGRIIYVDDGVLSFQVLEVVDDKTLKVKALNAGKICSHKGVNLPGTDVDLPALSEKDKEDLRFGVKNGVHMVFASFIRTANDVLTIREVLGEQGKDVKIIVKIENQQGVNNFDEILKVTDGVMVARGDLGIEIPAPEVLAVQKKLIAKSNLAGKPVICATQMLESMTYNPRPTRAEVSDVGNAILDGADCVMLSGETAKGNYPINAVTTMAETAVIAEQAIAYLPNYDDMRNCTPKPTSTTETVAASAVAAVFEQKAKAIIVLSTSGTTPRLVSKYRPNCPIILVTRCPRAARFSHLYRGVFPFVFEKEPVSDWTDDVEARINFGIEKAKEFGILKKGDTYVSIQGFKAGAGHSNTLQVSTV |
| 预测分子量 | 56.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDC19重组蛋白的3篇文献示例(注：CDC19为酿酒酵母丙酮酸激酶的基因名称，以下文献为模拟示例)：
---
1. **文献名称**：*Functional characterization of recombinant CDC19 pyruvate kinase in Saccharomyces cerevisiae*
**作者**：Smith J, et al.
**摘要**：通过重组表达纯化CDC19编码的丙酮酸激酶，研究其酶动力学特性及在酵母糖酵解途径中的调控机制，证实其磷酸化修饰对细胞周期进程的影响。
---
2. **文献名称**：*Structural insights into the allosteric regulation of CDC19 pyruvate kinase*
**作者**：Lee H, et al.
**摘要**：利用X射线晶体学解析重组CDC19蛋白的三维结构，揭示果糖-1.6-二磷酸(FBP)对其变构激活的分子机制，为靶向代谢疾病的药物设计提供依据。
---
3. **文献名称**：*Heterologous expression of yeast CDC19 in E. coli and its application in metabolic engineering*
**作者**：Zhang R, et al.
**摘要**：报道在大肠杆菌中高效表达重组酵母CDC19蛋白的策略，并验证其在体外合成丙酮酸途径中的催化效率，为微生物细胞工厂开发提供新工具。
---
注：若需真实文献，建议通过PubMed或Google Scholar以“CDC19 pyruvate kinase recombinant”为关键词检索。
**Background of CDC19 Recombinant Protein**
CDC19. also known as pyruvate kinase isoform M2 (PKM2), is a critical metabolic enzyme that catalyzes the final rate-limiting step in glycolysis, converting phosphoenolpyruvate (PEP) and ADP to pyruvate and ATP. This isoform is predominantly expressed in rapidly proliferating cells, including cancer cells, where it plays a dual role: regulating energy production and supporting biosynthetic pathways essential for cell growth. Unlike other pyruvate kinase isoforms, PKM2 exhibits unique dynamic switching between active tetrameric and less active dimeric states, allowing cancer cells to adapt metabolic flux to meet fluctuating nutrient and oxygen demands—a phenomenon central to the Warburg effect.
The recombinant form of CDC19 (PKM2) is produced using expression systems like *E. coli* or mammalian cells, enabling precise study of its structural, enzymatic, and non-metabolic functions. Recombinant PKM2 has been instrumental in uncovering its role beyond glycolysis, including gene regulation, protein kinase activity, and interaction with oncogenic signaling pathways (e.g., HIF-1α and mTOR). These discoveries highlight its potential as a therapeutic target in cancer, where aberrant PKM2 expression correlates with tumor progression, metastasis, and drug resistance.
Research using recombinant CDC19 protein has also advanced diagnostic applications. Its overexpression in bodily fluids or tissues serves as a biomarker for certain cancers. Additionally, inhibitors or activators targeting PKM2’s allosteric sites, designed using recombinant protein structures, are under investigation to modulate cancer metabolism. Despite challenges in isoform-specific targeting, CDC19 remains a focal point in metabolic disease and oncology research, bridging cellular energetics with malignant transformation.
×
